Currently recruiting and recently completed trials exploring the combination of ADC and IO agents
| Phase | Trial | Organ system | ADC | Antibody target | Payload (class) | IO agent (mechanism of action) | Status |
|---|---|---|---|---|---|---|---|
| I | NCT03523572 | Breast and urothelial | T-DXd | HER2 | DXd (DDA) | Nivo (ICI) | Recruiting (2018) |
| I | NCT04042701 | NSCLC, breast | T-DXd | HER2 | DXd (DDA) | Pembrolizumab (ICI) | Recruiting (2020) |
| I | NCT03364348 | Breast | T-DM1 | HER2 | DM1 (TI) | Utomilumab (CSA) | Recruiting (2017) |
| I | NCT03032107 | Breast | T-DM1 | HER2 | DM1 (TI) | Pembrolizumab (ICI) | Recruiting (2017) |
| II | NCT02924883 | Breast | T-DM1 | HER2 | DM1 (TI) | Atezolizumab (ICI) | Published 2021-negative trial |
| I | NCT02341625 | Solid organ, mesothelioma | BMS-986148 | Mesothelin | Unknown | Nivo (ICI) | Active (2015). Not recruiting |
| I | NCT03816358 | Pancreatic | Anetumab ravtansine | Mesothelin | DM4 (TI) | Nivo + ipilimumab/Nivo + chemo (ICI) | Recruiting (2019) |
| I | NCT03455556 | NSCLC | Anetumab ravtansine | Mesothelin | DM4 (TI) | Atezolizumab (ICI) | Completed (2018–2020) |
| I | NCT03126630 | Mesothelioma | Anetumab ravtansine | Mesothelin | DM4 (TI) | Pembrolizumab | Recruiting (2017) |
| I | NCT04448886 | HR+/HER2-breast | SG | Trop-2 | SN38 (TI) | Pembrolizumab (ICI) | Recruiting (2020) |
| II | NCT04468061 | TNBC | SG | Trop-2 | SN38 (TI) | Pembrolizumab | Recruiting (2020) |
| Ib/II | NCT03288545 | Urothelial | EV | Nectin-4 | MMAE (TI) | Pembrolizumab (ICI) | Recruiting (2017)—FDA breakthrough designation 2019 [177] |
| I | NCT03310957 | Breast | Ladiratuzumab vedotin | LIV-1 (zinc transporter subfamily) | MMAE (TI) | Pembrolizumab (ICI) | Recruiting (2018) |
| I | NCT03000257 | SCLC | Rovalpituzumab tesrine | DLL3 | SC-DR002 (DDA) | Budigalimab (PD-LI) | Completed (2019) |
| I/II | NCT03026166 | SCLC | Rovalpituzumab tesirine | DLL3 | SC-DR002 (DDA) | Nivo + ipilimumab (ICI) | P1 completed (2018), P2 halted (2019) due to high number of DLTs [178] |
| I | NCT03639194 | SCLC | SC-011 | Unknown | DDA | ABBV-181 (ICI) | Recruiting (2018) |
| I | NCT02099058 | NSCLC, solid tumours | Telisotuzumab vedotin | cMET | MMAE (TI) | Nivo | Recruiting (2014) |
| I | NCT03786081 | Cervical | TV | TF | MMAE (TI) | Pembrolizumab | Recruiting (2019) |
| I | NCT03729596 | Advanced solid tumours | MGC018 | Anti-B7-H3 | Unknown | MGA012 (ICI) | Recruiting (2018) |
| II | NCT03835819 | Endometrial | Mirvetuximab soravtansine | FRα | DM4 (TI) | Pembrolizumab | Recruiting (2019) |
cMET: mesenchymal epithelial transition factor; CSA: co-stimulatory agent; DDA: DNA damage agent; DLL3: delta-like ligand 3; FRα: folate receptor alpha; HR+: hormone receptor positive; LIV-1: zinc transporter ZIP6/SLC39A6; Nivo: nivolumab; TI: tubulin inhibitor; +: plus